{"id":51232,"date":"2026-03-30T00:34:18","date_gmt":"2026-03-30T00:34:18","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/51232\/"},"modified":"2026-03-30T00:34:18","modified_gmt":"2026-03-30T00:34:18","slug":"novo-says-priority-is-obesity-despite-investor-calls-to-expand","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/51232\/","title":{"rendered":"Novo Says Priority Is Obesity Despite Investor Calls to Expand"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVOB:DC\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novo Nordisk A\/S<\/a> is doubling down on obesity and diabetes, putting it at loggerheads with investors <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-03-26\/novo-chairman-faces-testy-investors-with-little-progress-so-far\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">calling for<\/a> the Danish drugmaker to diversify after it lost ground to rivals in the competitive weight-loss market.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The Ozempic maker\u2019s priority is to regain its competitiveness and get \u201cback on a par\u201d with <a href=\"https:\/\/www.bloomberg.com\/quote\/LLY:US\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Eli Lilly &amp; Co.<\/a>, Novo Chairman Lars Rebien Sorensen told reporters after the company\u2019s annual general meeting in Copenhagen on Thursday. At that point it could look at treatments for other health problems linked to obesity.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S is doubling down on obesity and diabetes, putting it at loggerheads with investors calling for&hellip;\n","protected":false},"author":2,"featured_media":51233,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[3660,28414,726,28415,691,16167,730,13602,28416,272,13578,591],"class_list":["post-51232","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-acquisitions","tag-c-suite","tag-chief-executive-officer","tag-consumer-goods","tag-drugs","tag-eli-lilly-co","tag-industries","tag-lars-rebien-sorensen","tag-mars-inc","tag-novo-nordisk","tag-novo-nordisk-a-s-b","tag-startups"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116315322108036725","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/51232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=51232"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/51232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/51233"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=51232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=51232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=51232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}